assess
wheez
frequenc
viral
etiolog
childhood
adolesc
asthma
risk
editor
viral
respiratori
wheez
ill
common
earli
childhood
mani
children
wheez
subsequ
develop
asthma
childhood
origin
asthma
coast
cohort
previous
report
develop
rhinoviru
rv
wheez
ill
infanc
earli
childhood
robust
predictor
subsequ
asthma
develop
highrisk
children
age
year
regardless
aeroallergen
sensit
risk
factor
howev
studi
similar
highrisk
birth
cohort
recent
report
number
lowerrespiratori
episod
first
year
life
oppos
specif
viral
bacteri
etiolog
associ
asthma
risk
suggest
specif
microbiolog
trigger
import
risk
later
asthma
develop
discrep
literatur
import
address
may
affect
risk
childhood
asthma
ascertain
accur
identif
highrisk
children
may
key
asthma
prevent
therefor
assess
contribut
etiolog
frequenc
wheez
ill
asthma
risk
patient
age
year
coast
birth
cohort
studi
includ
children
born
parent
either
allergi
asthma
hypothes
number
rv
wheez
ill
would
robust
predictor
asthma
develop
persist
compar
number
nonrv
wheez
ill
total
newborn
enrol
coast
studi
novemb
may
previous
describ
children
follow
prospect
age
year
age
year
qualifi
least
parent
requir
respiratori
allergi
defin
posit
result
aeroallergen
skin
test
andor
histori
physiciandiagnos
asthma
human
subject
committe
univers
wisconsin
approv
studi
inform
consent
obtain
parent
nasopharyng
mucu
sampl
collect
schedul
clinic
visit
month
time
acut
respiratori
ill
first
year
life
nasal
specimen
analyz
respiratori
virus
includ
respiratori
syncyti
viru
rv
influenza
type
b
parainfluenza
viru
type
adenoviru
metapneumovirus
coronavirus
bocavirus
enterovirus
use
cell
cultur
multiplex
pcr
multicodeplx
respiratori
viru
assay
eragen
bioscienc
madison
wi
addit
sampl
test
rv
seminest
rtpcr
use
extract
procedur
primer
optim
rv
specif
rv
type
determin
posit
specimen
use
partial
sequenc
relationship
frequenc
virusspecif
wheez
ill
develop
asthma
analyz
use
gener
addit
logist
regress
model
allow
examin
nonlinear
relationship
ill
frequenc
asthma
risk
wheez
ill
document
first
year
life
nasal
specimen
obtain
respiratori
virus
detect
wheez
ill
rv
detect
wheez
ill
fig
next
examin
impact
frequenc
viral
etiolog
wheez
ill
first
year
life
subsequ
asthma
risk
gener
addit
model
fit
scenario
one
ignor
etiolog
singl
smooth
term
total
number
wheez
ill
one
includ
etiolog
smooth
term
total
number
rv
wheez
ill
nonrv
wheez
ill
interact
model
compar
use
likelihood
ratio
test
everi
age
model
includ
etiolog
significantli
inform
asthma
risk
model
ignor
etiolog
year
p
year
p
year
p
year
p
fig
furthermor
asthma
risk
higher
multipl
rv
wheez
ill
compar
singl
rv
wheez
ill
rv
wheez
ill
compar
rv
wheez
ill
year
p
respect
studi
number
rv
wheez
episod
earli
childhood
close
associ
asthma
risk
find
support
concept
number
wheez
ill
irrespect
etiolog
import
asthma
risk
number
rv
wheez
ill
robust
asthma
predictor
therefor
number
etiolog
viral
wheez
episod
earli
life
import
predictor
risk
childhood
asthma
thu
import
pathogenspecif
respons
underestim
consid
mechan
drive
diseas
infect
specif
pathogen
lead
differ
immun
respons
respiratori
total
case
viru
identifi
wheez
ill
epithelium
moreov
like
host
factor
viral
etiolog
contribut
activ
immun
pathway
drive
diseas
import
identifi
order
elucid
effect
intervent
strategi
andor
modifi
diseas
progress
individu
child
one
potenti
explan
discrep
result
recent
report
bonnelykk
et
al
relat
differenti
frequenc
viral
detect
coast
compar
similar
copenhagen
prospect
studi
asthma
childhood
copsac
highrisk
cohort
detect
rv
vs
account
major
discrep
viral
detect
initi
use
set
primer
seminest
pcr
histor
identifi
previous
undetect
strain
human
rv
classifi
rvc
moreov
molecular
type
assay
recent
modifi
base
new
sequenc
inform
increas
sensit
specif
rv
detect
hypothes
molecular
techniqu
util
studi
robustli
detect
rv
includ
novel
rvc
type
sinc
rvc
close
associ
lower
respiratori
infect
wheez
incomplet
rvc
detect
could
lead
underestim
rv
infect
earli
life
relat
subsequ
asthma
addit
focu
wheez
episod
coast
versu
troublesom
lung
symptom
copsac
may
also
contribut
differ
studi
result
conclus
find
studi
suggest
viral
etiolog
earli
life
wheez
number
episod
import
subsequ
asthma
risk
preval
rv
wheez
ill
import
predictor
asthma
develop
highrisk
children
addit
studi
need
determin
whether
relationship
hold
true
unselect
birth
cohort
studi
increas
immun
reactiv
central
nervou
systemderiv
natur
present
peptid
patient
activ
multipl
sclerosi
editor
far
unequivoc
target
autoimmun
attack
multipl
sclerosi
ms
could
identifi
novel
approach
identifi
autoantigen
pursu
us
examin
antigen
local
present
central
nervou
system
cn
patient
ms
elut
identifi
mhcbound
peptid
follow
text
also
refer
mhc
ligandom
cn
patient
ms
present
studi
analyz
ifng
signatur
cytokin
h
cell
respons
pbmc
patient
ms
control
stimul
natur
present
peptid
elispot
see
method
section
tabl
articl
onlin
repositori
wwwjacionlin
org
patient
ms
take
part
studi
given
written
inform
consent
clinic
well
character
regard
diseas
state
calcul
number
specif
ifngsecret
cell
respons
panel
ligandom
peptid
see
tabl
articl
onlin
repositori
wwwjacionlineorg
addit
peptid
see
tabl
articl
onlin
repositori
wwwjacionlineorg
subtract
number
spot
control
well
number
spot
well
stimul
antigen
chose
assess
number
ifngsecret
cell
convinc
data
promin
role
h
cell
cn
autoimmun
clinic
studi
alter
peptid
ligand
specif
h
cell
found
increas
diseas
relaps
occur
treatment
data
show
pathogen
role
h
cell
also
absenc
h
cell
observ
specif
immun
respons
form
ifngsecret
cell
natur
present
peptid
control
patient
ms
indic
presenc
specif
cell
selfpeptid
normal
tcell
repertoir
compar
median
frequenc
ifngsecret
pbmc
control
group
patient
ms
observ
signific
differ
fig
subclassifi
ms
group
patient
activ
inact
diseas
fig
b
differ
patient
group
ms
signific
p
mannwhitney
u
test
howev
trend
toward
higher
number
ifngsecret
cell
patient
ms
activ
diseas
compar
control
reach
signific
p
mannwhitney
u
test
patient
activ
ms
show
higher
posit
reaction
test
ligandom
peptid
compar
patient
inact
diseas
control
see
fig
articl
onlin
repositori
wwwjacionlineorg
signific
differ
patient
activ
ms
inact
ms
p
result
differ
patient
ms
compar
result
control
b
higher
number
specif
ifngsecret
cell
ligandom
peptid
patient
ms
activ
diseas
compar
inact
diseas
p
mannwhitney
u
test
sampl
control
patient
ms
inact
diseas
patient
activ
diseas
test
p
mannwhitney
u
test
